B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Key Points

• B. Riley Financial raised its price target on Perspective Therapeutics from $11 to $13 and kept a "buy" rating, implying a potential upside of 165.20%; the stock carries a consensus Buy rating with an average target of $12.50.
• The company has a near-term clinical catalyst after acceptance of [212Pb]VMT-α-NET data for presentation at the AACR Annual Meeting, with earlier interim data showing no dose-limiting toxicities and encouraging anti-tumor signals.
• Financials remain weak—quarterly EPS was -$0.51 with just $0.04M in revenue, large negative margins and an expected FY EPS of -0.88—while the stock trades around $4.90, well below analyst targets, underscoring execution and financing risks.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) had its price target lifted by analysts at B. Riley Financial from $11.00 to $13.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. B. Riley Financial's target price would indicate a potential upside of 165.20% from the stock's previous close.

A number of other brokerages also recently issued reports on CATX. HC Wainwright lifted their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, January 30th. Truist Financial set a $12.00 target price on Perspective Therapeutics in a research report on Tuesday. BTIG Research restated a "buy" rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research note on Tuesday. UBS Group increased their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Piper Sandler initiated coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an "overweight" rating and a $16.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.50.

Perspective Therapeutics Trading Down 1.0%

Shares of NYSEAMERICAN:CATX traded down $0.05 during trading hours on Wednesday, hitting $4.90. The company's stock had a trading volume of 469,485 shares, compared to its average volume of 3,744,995. The firm's fifty day moving average price is $4.26 and its 200 day moving average price is $3.42. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The firm had revenue of $0.04 million during the quarter. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth $28,000. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock worth $29,000 after acquiring an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the 4th quarter worth about $31,000. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company's stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in Perspective Therapeutics during the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics News Roundup

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Multiple analysts reaffirmed or raised ratings and targets, signaling buy-side interest—UBS raised its price target from $7 to $8 and kept a "buy" rating. UBS raises PT to $8
• Positive Sentiment: Wedbush reaffirmed an "Outperform" rating and set an $11 price target, reinforcing bullish analyst sentiment. Wedbush reafirms Outperform, $11 PT
• Positive Sentiment: BTIG reiterated a "Buy" rating with a $14 target, adding to a cluster of high price targets (some firms have targets in the low-mid double digits). BTIG reaffirms Buy, $14 PT
• Positive Sentiment: Perspective had updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (April 20 presentation). Earlier interim data showed no dose-limiting toxicities and encouraging signals of anti-tumor activity in several cohorts—this is a visible clinical catalyst that could drive sentiment if the full poster confirms efficacy/safety trends. AACR acceptance press release
• Neutral Sentiment: Company filed a business update and full-year 2025 report describing program progress and expansion of production/finishing capabilities—useful context for longer-term commercialization but not an immediate earnings catalyst. Business update & full-year 2025 results
• Negative Sentiment: Royal Bank of Canada trimmed its price target from $18 to $14 (still "Outperform"), reflecting some downward PT revisions despite maintaining constructive views—this may temper upside expectations. RBC lowers PT to $14
• Negative Sentiment: Recent quarterly results showed a loss (EPS -$0.51) and minimal revenue, highlighting ongoing cash burn and weak near-term financials; these fundamentals can pressure the stock absent clear path to commercialization or financing. Quarterly results / press release

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.